Get access

Standard and new treatments in cutaneous B-cell lymphomas

Authors

  • Brigitte Dreno

    Corresponding author
    1. Department of Dermatology, CHU Hôtel Dieu, Nantes, France
      Professor Brigitte Dreno, Department of Dermatology, CHU Hôtel Dieu 44035 Nantes, France
      Tel: +33 240 083 118
      Fax: +33 240 083 117
      e-mail: brigitte.dreno@wanadoo.fr
    Search for more papers by this author

Professor Brigitte Dreno, Department of Dermatology, CHU Hôtel Dieu 44035 Nantes, France
Tel: +33 240 083 118
Fax: +33 240 083 117
e-mail: brigitte.dreno@wanadoo.fr

Abstract

Background:  Primary cutaneous B-cell lymphomas (PCBCL) are cutaneous non-Hodgkin lymphomas and can be classified clinically and by prognosis. The aim of this paper is to perform a review of standard and new treatments.

Method:  This paper provides a literature review of the different treatments of PCBCL.

Results:  Surgery and radiotherapy remain the standard therapies in isolated cutaneous lesions. Systemic or intralesional interferon (IFN)-α may be an alternative in PCBCL with diffuse cutaneous lesions. In aggressive forms with poor prognosis, polychemotherapy is the first line of treatment although rituximab and radioimmunotherapy are evolving therapeutic options.

Conclusion:  In the majority of cases, the treatment of CBCL is straightforward. In aggressive forms, new therapies and biologic therapies may be of real interest.

Get access to the full text of this article

Ancillary